Gene Therapy

Luk H. Vandenberghe, PhD , Harvard Medical School Associate Professor of Ophthalmology and Director of the Grousbeck Gene Therapy Center at Mass. Eye and Ear, has been named the first incumbent of the Grousbeck Family Chair in Gene Therapy at Mass. Eye...

OCU400, a novel gene therapy platform developed by Neena Haider, PhD, Harvard Medical School Associate Professor of Ophthalmology and Associate Scientist at the Schepens Eye Research Institute of Mass. Eye and Ear, and licensed to biopharmaceutical...

In Nature, Luk Vandenberghe, PhD, Harvard Medical School Associate Professor of Ophthalmology and Director of the Grousbeck Gene Therapy Center at Mass. Eye and Ear, discusses increasing the efficiency of gene therapies by manipulating the viral vectors...

New nonprofit organization will bring treatments to clinical trial for people at risk for blindness due to ultra-rare inherited retinal diseases. Boston, Mass. — Scientists and advocates today announced the formation of Odylia Therapeutics, a nonprofit...

Ocugen, Inc. has obtained an exclusive worldwide license to develop and commercialize future ophthalmology products based on groundbreaking technology developed by Neena Haider, PhD, Associate Professor of Ophthalmology. Learn about this technology and...

Improved delivery vector better penetrates the inner ear, also restores balance in a mouse model of Usher syndrome Boston, Mass. — In the summer of 2015, a team at Boston Children’s Hospital and Harvard Medical School reported restoring rudimentary...

Selecta is licensing Anc80 from Massachusetts Eye and Ear for a rare genetic disease with options on additional pre-specified indications. By combining Anc80 with Selecta’s investigational drug candidate, SVP-Rapamycin (SEL-110), Selecta is seeking to...